HeberNasvac: Development and Application in the Context of Chronic Hepatitis B
Résumé
The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low-and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
Domaines
Sciences du Vivant [q-bio]
Fichier principal
2024 HeberNasvac euroasian journal hepato-gastro.pdf (1.07 Mo)
Télécharger le fichier
Origine | Fichiers produits par l'(les) auteur(s) |
---|---|
licence |